DGI-024 Development of a Guide For Administering Antiviral Drugs by Gastrostomy or Nasogastric Tube: Abstact DGI-024 Table 1

Abstract

Background The number of patients infected by HIV and hepatitis has increased over the years. Some of them have swallowing difficulties that require the placement of nasogastric or gastrostomy tubes. These chronic treatments need high compliance rates to avoid antiviral drug resistance and, eventually, treatment failure. Purpose To review the existing antiviral drugs literature and develop administration recommendations for patients with swallowing problems. Materials and Methods Formulations and recommendations were obtained directly from the manufacturers, or by a PubMed search and a search on the Micromedex database, when information was not available. A guide published by SENPE with physicochemical and formulation properties of drugs was also checked. ResultsTable 1 shows the results. Extensive administration recommendations were found during literature searches but are not included in the present abstract. There was no information about the administration of adefovir, maraviroc or saquinavir through gastrostomy or nasogastric tube. Conclusions Treatment compliance is key to ensuring the success of chronic antiviral treatments and it is important to consider special situations, such as swallowing problems. This guide for nasogastric or enteral administration helps clinicians to choose the most appropriate treatment. Further research is needed to determine specific bioavailability data. Abstact DGI-024 Table 1Antiviral Drug Formulations and Administration Drug Solution available (mg/ml solution) Can be crushed/sprinkled abacavir 20 Yes didanosine 2 g/ml solution powder Use tablets, not capsules emtricitabine 10 Discouraged lamivudine 10, 5 Yes stavudine 1 Yes tenofovir Yes zidovudine 50 Discouraged efavirenz 30* Use capsules etravirine Yes nevirapine 10 Discouraged atazanavir 50 mg/1.5 g solution powder * Discouraged darunavir Yes fosamprenavir 50 indinavir Discouraged lopinavir/ritonavir 80/20 Discouraged nelfinavir Yes ritonavir 80 Discouraged tipranavir 100 raltegravir Yes abacavir/lamivudine ** abacavir/lamivudine/zidovudine ** zidovudine/lamivudine ** Yes tenofovir/emtricitabine Yes tenofovir/emtricitabine/efavirenz Discouraged boceprevir Discouraged telaprevir Discouraged ribavirin 40 Discouraged entecavir 0.05* telbivudine 20* Discouraged *Not in Spain **Individual drugs available in solution No conflict of interest.